Category: Musculoskeletal
-
Rapid Nexus study challenges neuropathy as the point of no return
New peer-reviewed research indicates nerve function is key to healing tissue once considered unsalvageable.
-
Conquering aging: A bold bid to fix the body’s interconnected systems
Unlimited Bio’s CEO discusses their attempt to achieve something never done before: combining multiple gene therapies in healthy individuals to reverse the ravages of time.
-
Teva unveils real-world findings for tardive dyskinesia treatment
Teva’s latest study finds Austedo and Austedo XR reduce involuntary movements and improve quality of life in tardive dyskinesia patients.
-
Tenon Medical shares surge on strategic sacro-pelvic asset deal
SiVantage deal expands Tenon’s multi-approach sacro-pelvic fusion offerings and market presence.
-
Emalex eyes FDA approval after Tourette syndrome drug’s Phase III win
The Phase III trial evaluating the company’s dopamine-1 receptor antagonist met primary endpoints in patients with Tourette syndrome.
-
Entrada’s stock climbs as US FDA lifts clinical hold on DMD drug
The US regulatory agency first placed the clinical hold in December 2022, with Entrada not disclosing the reason behind the clinical hold.
Latest posts
-
Navigating the Risks and Rewards of Biomarker-Based Surrogates and Accelerated Approval
The risks and rewards of biomarker-based surrogates are crucial for optimizing clinical trial outcomes and guiding effective treatments.
-
ASH25: Gallop’s LYT-200 shows unprecedented survival in AML
The company’s execs talk about the striking efficacy and safety signals seen in Phase I data, the science behind the molecule, and their vision for transforming AML therapy.
-
Promis reports first human evidence of aβ oligomer reduction by pmn310
PMN310 demonstrates dose-dependent reduction of amyloid-beta oligomers in human CSF, marking a key milestone in Alzheimer’s treatment development.
-
Urologic Health secures $11 million for non-invasive bladder monitoring
Urologic Health raises $11million seed funding to advance a catheter-free bladder monitoring platform toward FDA clearance and US market entry.
-
Novo Nordisk’s denecimig cuts bleeding in hemophilia A regardless of inhibitors
Phase III trial shows once‑monthly and once‑weekly denecimig (Mim8) significantly reduces annualized bleeding rate versus standard care, with up to 95% of patients bleed‑free.